Drug Profile
Danicopan - Alexion AstraZeneca Rare Disease
Alternative Names: 4471; ACH-0144471; ACH-4471; ACH-CFDIS; ALXN 2040; VoydeyaLatest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals
- Developer Achillion Pharmaceuticals; Alexion AstraZeneca Rare Disease
- Class Amides; Anti-inflammatories; Antianaemics; Eye disorder therapies; Halogenated hydrocarbons; Indazoles; Pyridines; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action Complement factor D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Paroxysmal nocturnal haemoglobinuria
- Phase II Dry macular degeneration
- Discontinued Haemolytic uraemic syndrome; Membranoproliferative glomerulonephritis
Most Recent Events
- 01 Apr 2024 Registered for Paroxysmal nocturnal haemoglobinuria (Adjunctive treatment) in USA (PO)
- 01 Apr 2024 US FDA label for danicopan has a black box warning for regarding serious infections caused by encapsulated bacteria
- 26 Feb 2024 CHMP of the EMA recommends approval of Danicopan for Paroxysmal nocturnal haemoglobinuria (Adjunctive treatment)